Comparison · NCT01297465-2bd8d983
Gonal-f® Plus Pergoveris® vs Pergoveris®: Biochemical Pregnancies Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Gonal-f® Plus Pergoveris® vs Pergoveris®: Biochemical Pregnancies Rate. Trial comparisons, record NCT01297465-2bd8d983. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01297465-2bd8d983
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.237 | 0.164 | 0.331 | wilson | |
| Risk in group 2 | 0.406 | 0.315 | 0.503 | wilson | |
| Risk difference, group 1 minus group 2 | -0.169 | -0.291 | -0.0385 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.584 | 0.381 | 0.896 | log | |
| Odds ratio, group 1 over group 2 | 0.455 | 0.246 | 0.84 | log | |
| Number needed to treat, for one fewer participant with the outcome on Gonal-f® Plus Pergoveris® than on Pergoveris® | 5.92 | 3.44 | 26 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Gonal-f® Plus Pergoveris® | Gonal-f® (follitropin alfa) 300 International Unit (IU) was administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5) followed by subsequent daily administration of Pergoveris® (follitropin alfa and lutropin alfa) 300 IU subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) (Ovidrel®/Ovitrelle®) administration day (at least 1 follicles greater than or equal to (\>=) 18 millimeter \[mm\]). On r-hCG day, 250 microgram of r-hCG was administered once subcutaneously. The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice. | 23 | 97 | OG000 |
| Group 2 | Pergoveris® | Pergoveris® (follitropin alfa and lutropin alfa) 300 IU was administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). On r-hCG (Ovidrel®/Ovitrelle®) day, 250 microgram of r-hCG was administered once subcutaneously. The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice. | 41 | 101 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Biochemical Pregnancies Rate
- Description
Biochemical pregnancy was defined as the pregnancy diagnosed only by the detection of human chorionic gonadotropin (hCG) in serum or urine and that does not develop into a clinical pregnancy. Participants with beta- hCG concentration greater than 10 international units per liter (IU/L) were considered as biochemical pregnant.
- Time frame
- Days 15-20 post r-hCG day (end of stimulation cycle [approximately 11 days])
- Population
Mod-ITT population included all the randomized participants who had received at least one dose of GONAL-f® or Pergoveris®, and completed the primary efficacy assessment. . N (number of participants analyzed) signifies those participants who had their embryo transfer in study treatment cycle.
Source ClinicalTrials.gov
Trial
- Title
- PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
- NCT number
- NCT01297465
- Phases
- PHASE3
- Conditions
- Assisted Reproductive Techniques, Reproductive Technology, Assisted
- Interventions
- Gonal-f®, Pergoveris®, Pergoveris®, Recombinant human chorionic gonadotropin (r-hCG)
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Results first posted
- 2014-02-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01297465?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01297465-2bd8d983